Drug Trial Radar · NCT06491563
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Aug 6, 2024
Primary completion
Aug 5, 2026
Study completion Aug 5, 2026
Sponsor
- Lead sponsor
- Brii Biosciences LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Vir Biotechnology, Inc.
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
Conditions
- For Treatment of Chronic Hepatitis B Virus Infection
Interventions
BRII-179Biological
BRII-179 will be given via intramuscular injection
BRII-835 (VIR-2218)Drug
BRII-835 will be given via subcutaneous injection
PEG-IFNαBiological
PEG-IFNα will be given via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepointTime frame: 24 weeks post end of treatment
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site 86004
Beijing, Beijing Municipality, China
Investigative Site 86009
Beijing, Beijing Municipality, China
Investigative Site 86015
Xiamen, Fujian, China
Investigative Site 86012
Foshan, Guangdong, China
Investigative Site 86001
Guangzhou, Guangdong, China
Investigative Site 86013
Guangzhou, Guangdong, China
Investigative Site 86002
Shenzhen, Guangdong, China
Investigative Site 86003
Shanghai, Shanghai Municipality, China
Investigative Site 86008
Shanghai, Shanghai Municipality, China
Investigative Site 86007
Chengdu, Sichuan, China
Investigative Site 86011
Chengdu, Sichuan, China
Investigative Site 86005
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.